<!DOCTYPE html>
<html lang="en"><head>
<script src="avir talk_files/libs/clipboard/clipboard.min.js"></script>
<script src="avir talk_files/libs/quarto-html/tabby.min.js"></script>
<script src="avir talk_files/libs/quarto-html/popper.min.js"></script>
<script src="avir talk_files/libs/quarto-html/tippy.umd.min.js"></script>
<link href="avir talk_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="avir talk_files/libs/quarto-html/light-border.css" rel="stylesheet">
<link href="avir talk_files/libs/quarto-html/quarto-html.min.css" rel="stylesheet" data-mode="light">
<link href="avir talk_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<link href="avir talk_files/libs/quarto-contrib/fontawesome6-0.1.0/all.css" rel="stylesheet">
<link href="avir talk_files/libs/quarto-contrib/fontawesome6-0.1.0/latex-fontsize.css" rel="stylesheet"><meta charset="utf-8">
  <meta name="generator" content="quarto-1.4.549">

  <title>avir-talk</title>
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
  <link rel="stylesheet" href="avir talk_files/libs/revealjs/dist/reset.css">
  <link rel="stylesheet" href="avir talk_files/libs/revealjs/dist/reveal.css">
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      width: 0.8em;
      margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
      vertical-align: middle;
    }
    /* CSS for citations */
    div.csl-bib-body { }
    div.csl-entry {
      clear: both;
      margin-bottom: 0em;
    }
    .hanging-indent div.csl-entry {
      margin-left:2em;
      text-indent:-2em;
    }
    div.csl-left-margin {
      min-width:2em;
      float:left;
    }
    div.csl-right-inline {
      margin-left:2em;
      padding-left:1em;
    }
    div.csl-indent {
      margin-left: 2em;
    }  </style>
  <link rel="stylesheet" href="avir talk_files/libs/revealjs/dist/theme/quarto.css">
  <link href="avir talk_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.css" rel="stylesheet">
  <link href="avir talk_files/libs/revealjs/plugin/reveal-menu/menu.css" rel="stylesheet">
  <link href="avir talk_files/libs/revealjs/plugin/reveal-menu/quarto-menu.css" rel="stylesheet">
  <link href="avir talk_files/libs/revealjs/plugin/quarto-support/footer.css" rel="stylesheet">
  <style type="text/css">

  .callout {
    margin-top: 1em;
    margin-bottom: 1em;  
    border-radius: .25rem;
  }

  .callout.callout-style-simple { 
    padding: 0em 0.5em;
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
    display: flex;
  }

  .callout.callout-style-default {
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
  }

  .callout .callout-body-container {
    flex-grow: 1;
  }

  .callout.callout-style-simple .callout-body {
    font-size: 1rem;
    font-weight: 400;
  }

  .callout.callout-style-default .callout-body {
    font-size: 0.9rem;
    font-weight: 400;
  }

  .callout.callout-titled.callout-style-simple .callout-body {
    margin-top: 0.2em;
  }

  .callout:not(.callout-titled) .callout-body {
      display: flex;
  }

  .callout:not(.no-icon).callout-titled.callout-style-simple .callout-content {
    padding-left: 1.6em;
  }

  .callout.callout-titled .callout-header {
    padding-top: 0.2em;
    margin-bottom: -0.2em;
  }

  .callout.callout-titled .callout-title  p {
    margin-top: 0.5em;
    margin-bottom: 0.5em;
  }
    
  .callout.callout-titled.callout-style-simple .callout-content  p {
    margin-top: 0;
  }

  .callout.callout-titled.callout-style-default .callout-content  p {
    margin-top: 0.7em;
  }

  .callout.callout-style-simple div.callout-title {
    border-bottom: none;
    font-size: .9rem;
    font-weight: 600;
    opacity: 75%;
  }

  .callout.callout-style-default  div.callout-title {
    border-bottom: none;
    font-weight: 600;
    opacity: 85%;
    font-size: 0.9rem;
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-default div.callout-content {
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-simple .callout-icon::before {
    height: 1rem;
    width: 1rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 1rem 1rem;
  }

  .callout.callout-style-default .callout-icon::before {
    height: 0.9rem;
    width: 0.9rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 0.9rem 0.9rem;
  }

  .callout-title {
    display: flex
  }
    
  .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  .callout.no-icon::before {
    display: none !important;
  }

  .callout.callout-titled .callout-body > .callout-content > :last-child {
    padding-bottom: 0.5rem;
    margin-bottom: 0;
  }

  .callout.callout-titled .callout-icon::before {
    margin-top: .5rem;
    padding-right: .5rem;
  }

  .callout:not(.callout-titled) .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  /* Callout Types */

  div.callout-note {
    border-left-color: #4582ec !important;
  }

  div.callout-note .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-note.callout-style-default .callout-title {
    background-color: #dae6fb
  }

  div.callout-important {
    border-left-color: #d9534f !important;
  }

  div.callout-important .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-important.callout-style-default .callout-title {
    background-color: #f7dddc
  }

  div.callout-warning {
    border-left-color: #f0ad4e !important;
  }

  div.callout-warning .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-warning.callout-style-default .callout-title {
    background-color: #fcefdc
  }

  div.callout-tip {
    border-left-color: #02b875 !important;
  }

  div.callout-tip .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-tip.callout-style-default .callout-title {
    background-color: #ccf1e3
  }

  div.callout-caution {
    border-left-color: #fd7e14 !important;
  }

  div.callout-caution .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-caution.callout-style-default .callout-title {
    background-color: #ffe5d0
  }

  </style>
  <style type="text/css">
    .reveal div.sourceCode {
      margin: 0;
      overflow: auto;
    }
    .reveal div.hanging-indent {
      margin-left: 1em;
      text-indent: -1em;
    }
    .reveal .slide:not(.center) {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide.scrollable {
      overflow-y: auto;
    }
    .reveal .footnotes {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide .absolute {
      position: absolute;
      display: block;
    }
    .reveal .footnotes ol {
      counter-reset: ol;
      list-style-type: none; 
      margin-left: 0;
    }
    .reveal .footnotes ol li:before {
      counter-increment: ol;
      content: counter(ol) ". "; 
    }
    .reveal .footnotes ol li > p:first-child {
      display: inline-block;
    }
    .reveal .slide ul,
    .reveal .slide ol {
      margin-bottom: 0.5em;
    }
    .reveal .slide ul li,
    .reveal .slide ol li {
      margin-top: 0.4em;
      margin-bottom: 0.2em;
    }
    .reveal .slide ul[role="tablist"] li {
      margin-bottom: 0;
    }
    .reveal .slide ul li > *:first-child,
    .reveal .slide ol li > *:first-child {
      margin-block-start: 0;
    }
    .reveal .slide ul li > *:last-child,
    .reveal .slide ol li > *:last-child {
      margin-block-end: 0;
    }
    .reveal .slide .columns:nth-child(3) {
      margin-block-start: 0.8em;
    }
    .reveal blockquote {
      box-shadow: none;
    }
    .reveal .tippy-content>* {
      margin-top: 0.2em;
      margin-bottom: 0.7em;
    }
    .reveal .tippy-content>*:last-child {
      margin-bottom: 0.2em;
    }
    .reveal .slide > img.stretch.quarto-figure-center,
    .reveal .slide > img.r-stretch.quarto-figure-center {
      display: block;
      margin-left: auto;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-left,
    .reveal .slide > img.r-stretch.quarto-figure-left  {
      display: block;
      margin-left: 0;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-right,
    .reveal .slide > img.r-stretch.quarto-figure-right  {
      display: block;
      margin-left: auto;
      margin-right: 0; 
    }
  </style>
</head>
<body class="quarto-light">
  <div class="reveal">
    <div class="slides">


<section id="the-changing-landscape-of-hematological-malignancy-treatment" class="slide level2" data-background-video="/images/bubbles.mp4" data-background-video-loop="true" data-background-video-muted="true" data-background-opacity="0.5">
<h2>The Changing Landscape of Hematological <br> Malignancy Treatment</h2>
<p><br></p>
<h3 id="implications-for-antifungal-therapy">Implications for antifungal therapy</h3>
<p><br> <br></p>
<center>
<p>Russell E. Lewis, Pharm.D., FCCP <br> Associate Professor of Medicine, Infectious Diseases <br> Department of Molecular Medicine, University of Padua <br> Hematopoietic Stem Cell Transplant Program and Cell Therapies <br>Ca’ Foncello Hospital, Treviso, Italy</p>
<p><br> <i class="fa-solid fa-envelope fa-1x" aria-label="envelope"></i> russelledward.lewis@unipd.it <br> <i class="fa-brands fa-github fa-1x" aria-label="github"></i> <a href="https://github.com/Russlewisbo/ESCMID_2022_talk">https://github.com/Russlewisbo</a></p>
<p><img data-src="University_of_Padua_seal.svg" class="absolute" style="top: 500px; left: 150px; width: 150px; height: 100px; "></p>

</center><aside><div>
<p>June 26, 2024</p>
</div></aside></section>
<section id="disclosures" class="slide level2">
<h2>Disclosures</h2>
<p><br></p>
<div>
<ul>
<li><strong>Research funding</strong>: Merck &amp; Co Inc., Gilead Sciences</li>
<li><strong>Speaking</strong>: Avir, Gilead</li>
<li><strong>Consultancy</strong>: F2G, Scynexis, Basilea, Gilead Sciences, Cidara Therapeutics</li>
</ul>
</div>
<p><br></p>
</section>
<section id="agenda" class="slide level2" data-background-image="bonemarrow.png">
<h2>Agenda</h2>
<p><br></p>
<ul>
<li class="fragment">How will new therapies impact the epidemiology of invasive fungal infections?</li>
<li class="fragment">What are the risks of toxicity and drug interactions with these newer therapies?</li>
<li class="fragment">Is their a unique role for isavuconazole versus other triazoles?</li>
</ul>
</section>
<section id="the-cure-of-leukemia-through-the-optimists-prism" class="slide level2 smaller">
<h2>“The cure of leukemia through the optimist’s prism”</h2>
<p><br></p>
<table style="width:100%;">
<colgroup>
<col style="width: 28%">
<col style="width: 61%">
<col style="width: 9%">
</colgroup>
<thead>
<tr class="header">
<th>Disease</th>
<th>Current/ <br> future therapies*</th>
<th>Survival <br> (5 year)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Hairy cell leukemia</strong></td>
<td>Clofarabine + <span style="color:red;">gemtuzumab ozogamicin (GO)</span></td>
<td>90%</td>
</tr>
<tr class="even">
<td><strong>Acute premyelocytic leukemia</strong></td>
<td>ATRA + arsenic ± <span style="color:red;">GO</span></td>
<td>80-90%</td>
</tr>
<tr class="odd">
<td><strong>AML</strong> <br><strong>(core binding factor positive)</strong></td>
<td>FLAG-<span style="color:red;">GO</span> ± IDA, alloHSCT if MRD positive, if indicated, oral <span style="color:red;">AZA/HMA with venetoclax or FLT3/IDH or menin inhibitors</span></td>
<td>80-90%+</td>
</tr>
<tr class="even">
<td><strong>AML</strong> <br><strong>(younger fit)</strong></td>
<td>FLAG-IDA and <span style="color:red;">venetoclax</span>, CLIA and <span style="color:red;">venetoclax</span></td>
<td>50-60%</td>
</tr>
<tr class="odd">
<td><strong>AML</strong> <br> <strong>(older, unfit, complex karyotype, T-53 mutations, MECOM)</strong></td>
<td>Low-intensity triple nucleosides (cladarabine, cytarabine and <span style="color:red;">HMAs + venetoclax; HMAs + venetoclax + targeted therapy</span></td>
<td>40-50%</td>
</tr>
<tr class="even">
<td><strong>ALL &lt; 60 years</strong></td>
<td>HyperCVAD + <span style="color:red;">CD19/CD20 targeted antibodies</span></td>
<td>60-70%</td>
</tr>
<tr class="odd">
<td><strong>ALL &gt; 60 years</strong></td>
<td>Mini-hyper CVAD+ <span style="color:red;">inotuzumab; blinatumab + ponatinib</span></td>
<td>50%</td>
</tr>
<tr class="even">
<td><strong>Ph-positive ALL</strong></td>
<td>HyperCVAD + <span style="color:red;">ponatinib; blinatumab + ponatinib</span></td>
<td>70-80%?</td>
</tr>
</tbody>
</table>

<aside><div>
<p><span class="citation" data-cites="kantarjian2021 kantarjian2022J">(<a href="#/references" role="doc-biblioref" onclick="">H. Kantarjian et al. 2021</a>; <a href="#/references" role="doc-biblioref" onclick="">H. M. Kantarjian et al. 2022</a>)</span> <br></p>
<p>*some therapies investigational or not licensed in Canada. Abbreviations: ALL, acute lymphoblastic leukemia; CLIA, cladribine, high-dose cytarabine, and idarubicin; FLAG-GO, fludarabine, high-dose cytarabine, and gemtuzumab ozogamicin; FLAG-GO ± IDA, fludarabine, cytarabine, granulocyte colony-stimulating factor, and gemtuzumab ozogamicin ± idarubicin; FLAG-IDA, fludarabine, high-dose cytarabine, and idarubicin; GO, gemtuzumab ozogamicin; HMA, hypomethylating agent; hyper-CVAD, hyperfractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone; mini-hyper-CVD, mini-hyperfractionated cyclophosphamide, vincristine, dexamethasone; Ph, Philadelphia chromosome; SCT, stem cell transplantation.</p>
</div></aside></section>
<section id="the-cure-of-leukemia-through-the-optimists-prism-1" class="slide level2 smaller">
<h2>“The cure of leukemia through the optimist’s prism”</h2>
<table style="width:99%;">
<colgroup>
<col style="width: 6%">
<col style="width: 77%">
<col style="width: 14%">
</colgroup>
<thead>
<tr class="header">
<th>Disease</th>
<th>Current/ future therapy*</th>
<th>Survival <br>(5 year)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>CML</strong></td>
<td><span style="color:red;">BCR-Abl1 tyrosine kinase inhibitors (imatinib, dasatinib, bosutinib, nilotunib, ponatinib)</span>, alloHSCT</td>
<td>85-90%</td>
</tr>
<tr class="even">
<td><strong>CLL</strong></td>
<td><span style="color:red;">Ibrutinib, other BTKIs (acalabrutinib, zanubrutinib, pirtobrutinib)</span></td>
<td>80-90% +</td>
</tr>
<tr class="odd">
<td><strong>MDS</strong></td>
<td><span style="color:red;">Parenteral HMAs, oral HMAs, venetoclax, others</span></td>
<td>40% +</td>
</tr>
</tbody>
</table>

<aside><div>
<p><span class="citation" data-cites="kantarjian2021 kantarjian2022J">(<a href="#/references" role="doc-biblioref" onclick="">H. Kantarjian et al. 2021</a>; <a href="#/references" role="doc-biblioref" onclick="">H. M. Kantarjian et al. 2022</a>)</span> <br></p>
<p>*some therapies investigational or not licensed in Canada. Abbreviations: ALL, acute lymphoblastic leukemia; CLIA, cladribine, high-dose cytarabine, and idarubicin; FLAG-GO, fludarabine, high-dose cytarabine, and gemtuzumab ozogamicin; FLAG-GO ± IDA, fludarabine, cytarabine, granulocyte colony-stimulating factor, and gemtuzumab ozogamicin ± idarubicin; FLAG-IDA, fludarabine, high-dose cytarabine, and idarubicin; GO, gemtuzumab ozogamicin; HMA, hypomethylating agent; hyper-CVAD, hyperfractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone; mini-hyper-CVD, mini-hyperfractionated cyclophosphamide, vincristine, dexamethasone; Ph, Philadelphia chromosome; SCT, stem cell transplantation.</p>
</div></aside></section>
<section id="how-are-newer-targeted-therapies" class="slide level2" data-background-image="bonemarrow.png" data-background-opacity="0.5">
<h2>How are newer targeted therapies…</h2>
<p><br> <br></p>
<ul>
<li class="fragment">Changing the epidemiology of invasive fungal diseases?</li>
<li class="fragment">Changing the risk of drug interactions and toxicity with antifungal therapy?</li>
<li class="fragment">Is there a unique role for isavuconazole?</li>
</ul>
</section>
<section id="how-is-invasive-fungal-disease-risk-altered-by-targeted-therapies" class="slide level2" data-background-image="bonemarrow.png">
<h2><br> <br> <br> <br> <br>How is invasive fungal disease risk altered <br> by targeted therapies?</h2>
</section>
<section id="unexpected-consequences-of-targeted-therapy" class="slide level2">
<h2>Unexpected consequences of targeted therapy?</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="burger_NEJM.png" class="quarto-figure quarto-figure-center" width="3028"></p>
</figure>
</div>

<aside><div>
<p>In response to phagocytosis of A. fumigatus by macrophages, BTK activates the calcineurin- NFAT pathway and potentiates TNF-α signaling <span class="citation" data-cites="burger2015 chamilos2018 herbst2015">(<a href="#/references" role="doc-biblioref" onclick="">Burger et al. 2015</a>; <a href="#/references" role="doc-biblioref" onclick="">Chamilos, Lionakis, and Kontoyiannis 2018</a>; <a href="#/references" role="doc-biblioref" onclick="">Herbst et al. 2015</a>)</span></p>
</div></aside></section>
<section id="btk-drives-neutrophil-activation-for-sterilizing-antifungal-immunity" class="slide level2">
<h2>BTK drives neutrophil activation for sterilizing antifungal immunity</h2>

<aside><div>
<p><span class="citation" data-cites="desai2024">(<a href="#/references" role="doc-biblioref" onclick="">Desai et al. 2024</a>)</span></p>
<p>Second-generation BTK inhibitors acalabrutinib and zanubrutinib have since been granted FDA approval and possess greater binding selectivity and fewer off-target effects compared to ibrutinib.</p>
</div></aside></section>
<section id="ibrutinib-associated-aspergillosis" class="slide level2">
<h2>Ibrutinib-associated aspergillosis</h2>
<div class="columns">
<div class="column" style="width:50%;">
<p><br></p>
<div>
<div class="quarto-figure quarto-figure-left">
<figure>
<p><img data-src="MRI.png" class="quarto-figure quarto-figure-left"></p>
</figure>
</div>
</div>
</div><div class="column" style="width:50%;">
<p><br></p>
<p><br></p>
<ul>
<li class="fragment">Retrospective French surveillance study identified 33 cases of aspergillosis in ibrutinib-treated patients with CLL</li>
<li class="fragment"><span style="color:red;">CNS aspergillosis in 11/27 (40%)</span>, most cases within 3 months of starting therapy</li>
<li class="fragment">All patients had refractory/relapsed CLL and other predisposing risk factors</li>
</ul>
</div>
</div>

<aside><div>
<p><span class="citation" data-cites="ghez2018 chamilos2018">(<a href="#/references" role="doc-biblioref" onclick="">Ghez et al. 2018</a>; <a href="#/references" role="doc-biblioref" onclick="">Chamilos, Lionakis, and Kontoyiannis 2018</a>)</span></p>
</div></aside></section>
<section id="fungal-infections-in-patients-receiving-ibrutinib-for-lymphoid-cancers" class="slide level2">
<h2>Fungal infections in patients receiving <br> ibrutinib for lymphoid cancers</h2>
<div class="columns">
<div class="column" style="width:60%;">
<center>
Data from MSKCC, New York
</center>
<div>
<p><img data-src="ibrutinib_onset.png"></p>
</div>
</div><div class="column" style="width:40%;">
<p><br> <br></p>
<ul>
<li class="fragment"><strong>In a second, retrospective study from MDACC (2014-2018):</strong>
<ul>
<li class="fragment">21 (2.5%) with proven/probable invasive mold infection</li>
<li class="fragment">Primarily pneumonia</li>
<li class="fragment">Mostly <em>Aspergillus</em> spp.</li>
<li class="fragment">Risk factors: monocytopenia, ≥ 3 prior CLL therapies</li>
</ul></li>
</ul>
</div>
</div>

<aside><div>
<p><span class="citation" data-cites="varughese2018 frei2020J">(<a href="#/references" role="doc-biblioref" onclick="">Varughese et al. 2018</a>; <a href="#/references" role="doc-biblioref" onclick="">Frei et al. 2020</a>)</span></p>
</div></aside></section>
<section id="section" class="slide level2">
<h2></h2>
<p><img data-src="Lancet%20_DI.png"></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="Lancet%20Haematology.png" class="quarto-figure quarto-figure-center"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="bruggemann2022 stemler2022J">(<a href="#/references" role="doc-biblioref" onclick="">R. J. Brüggemann et al. 2022</a>; <a href="#/references" role="doc-biblioref" onclick="">Stemler et al. 2022</a>)</span></p>
</div></aside></section>
<section id="managing-fungal-infection-risks-with-novel-therapies-for-aml" class="slide level2">
<h2>Managing fungal infection risks with <br> novel therapies for AML</h2>
<h3 id="eha-consensus-recommendations">EHA consensus recommendations</h3>
<p><br></p>
<ul>
<li class="fragment">Systematic review of the literature, recommendations developed using GRADE framework (4977 publications evaluated)</li>
<li class="fragment">Outcomes evaluated:
<ul>
<li class="fragment">Incidence of invasive fungal disease (IFD)</li>
<li class="fragment">Prolongation of hospitalization</li>
<li class="fragment">Days spent in ICU/mortality associated with IFD</li>
<li class="fragment">Potential DDIs</li>
</ul></li>
<li class="fragment"><strong>Evidence-based recommendations were developed for hypomethylating agents (HMAs), FLT-3 inhibitors, and venetoclax-HMA combinations</strong></li>
</ul>

<aside><div>
<p><span class="citation" data-cites="stemler2022J">(<a href="#/references" role="doc-biblioref" onclick="">Stemler et al. 2022</a>)</span></p>
</div></aside></section>
<section id="summary-of-eha-recommendations-1" class="slide level2">
<h2>Summary of EHA recommendations-1</h2>
<p><br></p>
<ul>
<li class="fragment"><strong>Hypomethylating agent monotherapy:</strong>
<ul>
<li class="fragment">Standard use or prophylaxis not recommended</li>
<li class="fragment">Risk of IFI increased in patients with neutropenia at onset of treatment, prior intensive chemotherapy → conditional recommendation for prophylaxis</li>
</ul></li>
<li class="fragment"><strong>FLT3 inhibitors (midostaurin, gilteritinib)</strong>
<ul>
<li class="fragment">Antifungal prophylaxis recommended during induction chemotherapy</li>
<li class="fragment">Conditional recommendation for prophylaxis during consolidation in patients with risk factors (prior IFI, prolonged neutropenia)</li>
<li class="fragment">Lack of clear medical guidance for managing drug interactions</li>
<li class="fragment">Close monitoring favoured over empiric FLT-3 inhibitor dose reduction</li>
</ul></li>
</ul>

<aside><div>
<p><span class="citation" data-cites="stemler2022J">(<a href="#/references" role="doc-biblioref" onclick="">Stemler et al. 2022</a>)</span></p>
</div></aside></section>
<section id="summary-of-eha-recommendations-2" class="slide level2">
<h2>Summary of EHA recommendations-2</h2>
<p><br></p>
<ul>
<li class="fragment"><strong>Venetoclax</strong>
<ul>
<li class="fragment">Risk of IFI increased in patients with neutropenia at onset of treatment, prior intensive chemotherapy, or prolonged neutropenia with venetoclax</li>
<li class="fragment">Conditional recommendation to administer prophylaxis</li>
<li class="fragment">Careful management of drug interactions with triazoles</li>
</ul></li>
</ul>

<aside><div>
<p><span class="citation" data-cites="stemler2022J">(<a href="#/references" role="doc-biblioref" onclick="">Stemler et al. 2022</a>)</span></p>
</div></aside></section>
<section id="venetoclax-dose-adjustment-with-triazoles" class="slide level2 scrollable">
<h2>Venetoclax dose-adjustment with triazoles</h2>
<p><br></p>
<center>
<p>Venetoclax + hypomethylating agents for AML;</p>
<p>Co-administration with posaconazole ↑ venetoclax AUC 8-fold</p>
</center>
<p><br></p>
<table style="width:98%;">
<colgroup>
<col style="width: 13%">
<col style="width: 15%">
<col style="width: 35%">
<col style="width: 33%">
</colgroup>
<thead>
<tr class="header">
<th><strong>Day</strong></th>
<th><strong>Full dose</strong></th>
<th><strong>Moderate CYP3A4 inhibitor</strong><sup>1</sup></th>
<th><strong>Strong CYP3A4 inhibitor</strong><sup>2</sup></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Day 1</td>
<td>100 mg</td>
<td>50 mg</td>
<td>10 mg</td>
</tr>
<tr class="even">
<td>Day 2</td>
<td>200 mg</td>
<td>100 mg</td>
<td>20 mg</td>
</tr>
<tr class="odd">
<td>Day 3</td>
<td>400 mg</td>
<td>200 mg</td>
<td>50 mg</td>
</tr>
<tr class="even">
<td>Day 4-28</td>
<td>400 mg</td>
<td>200 mg</td>
<td>70 mg</td>
</tr>
</tbody>
</table>

<aside><div>
<p><span class="citation" data-cites="stemler2022J bhatnagar2021J">(<a href="#/references" role="doc-biblioref" onclick="">Stemler et al. 2022</a>; <a href="#/references" role="doc-biblioref" onclick="">Bhatnagar et al. 2021</a>)</span></p>
</div><ol class="aside-footnotes"><li id="fn1"><p>fluconazole, isavuconazole</p></li><li id="fn2"><p>voriconazole, posaconazole</p></li></ol></aside></section>
<section id="triazole-prophylaxis-increases-duration-of-thrombocytopenia-but-not-neutropenia-or-infections-with-dose-adjusted-venetoclax" class="slide level2">
<h2>Triazole prophylaxis increases duration of thrombocytopenia but not neutropenia or infections with dose-adjusted venetoclax</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="venetoclax_Rausch.png" class="quarto-figure quarto-figure-center"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="rausch2019">(<a href="#/references" role="doc-biblioref" onclick="">Rausch et al. 2019</a>)</span></p>
</div></aside></section>
<section id="cyp450-interactions-the-achilles-heel-of-triazoles" class="slide level2">
<h2>CYP450 Interactions: The achilles heel of triazoles</h2>
<center>
75-85% of patients receiving mold-active triazoles have serious drug interactions
</center>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="cyp_interactions.png" class="quarto-figure quarto-figure-center" width="600"></p>
</figure>
</div>
<p><br></p>

<aside><div>
<p><span class="citation" data-cites="bruggemann2009a andes2016">(<a href="#/references" role="doc-biblioref" onclick="">R. J. M. Brüggemann et al. 2009</a>; <a href="#/references" role="doc-biblioref" onclick="">Andes et al. 2016</a>)</span></p>
</div></aside></section>
<section id="pkpd-properties-of-small-molecule-kinase-inhibitors" class="slide level2 smaller">
<h2>PK/PD Properties of Small Molecule Kinase Inhibitors</h2>
<p><br> <br></p>
<table style="width:98%;">
<colgroup>
<col style="width: 9%">
<col style="width: 12%">
<col style="width: 12%">
<col style="width: 13%">
<col style="width: 12%">
<col style="width: 24%">
<col style="width: 12%">
</colgroup>
<thead>
<tr class="header">
<th>Drug</th>
<th>Venetoclax</th>
<th>Midostraurin</th>
<th>Gilteritinib</th>
<th>Ivosidenib</th>
<th>Enasidinib</th>
<th>Glasdegib</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Specificity (targets)</td>
<td>BCL2</td>
<td>FLT3</td>
<td>FLT3</td>
<td>IDH1</td>
<td>IDH2</td>
<td>Hedgehog pathway</td>
</tr>
<tr class="even">
<td>Hepatic</td>
<td><span style="color:red;">CYP3A4</span></td>
<td><span style="color:red;">CYP3A4</span></td>
<td><span style="color:red;">CYP3A4/5</span></td>
<td><span style="color:red;">CYP3A4/5</span></td>
<td><span style="color:red;">Multiple CYP enzymes including CYP3A4</span></td>
<td><span style="color:red;">CYP3A4/5</span></td>
</tr>
<tr class="odd">
<td>Efflux</td>
<td>Substrate of PgP, BCRP</td>
<td>Not a substrate</td>
<td>Substrate of PgP, not BCRP, OATP</td>
<td>Substrate PgP, but not BRCP</td>
<td>Not a substrate of BCRP pr PgP</td>
<td>Substrate for PGP, BCRP</td>
</tr>
</tbody>
</table>

<aside><div>
<p><span class="citation" data-cites="megias-vericat2020J">(<a href="#/references" role="doc-biblioref" onclick="">Megías-Vericat et al. 2020</a>)</span></p>
</div></aside></section>
<section id="toxicities-of-small-molecule-kinase-inhibitors" class="slide level2">
<h2>Toxicities of small-molecule kinase inhibitors</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="targeted%20therapy%20toxicities.png" class="quarto-figure quarto-figure-center"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="wang2020a">(<a href="#/references" role="doc-biblioref" onclick="">Wang and Baron 2020</a>)</span></p>
</div></aside></section>
<section id="just-avoid-triazoles" class="slide level2">
<h2>Just avoid triazoles?</h2>
<p><br></p>

<img data-src="avoid%20triazoles.png" class="quarto-figure quarto-figure-center r-stretch"></section>
<section id="the-problems-with-echinocandin-prophylaxis" class="slide level2">
<h2>The problems with echinocandin prophylaxis</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="echinocandin.png" class="quarto-figure quarto-figure-center"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="gomes2014">(<a href="#/references" role="doc-biblioref" onclick="">Gomes et al. 2014</a>)</span></p>
</div></aside></section>
<section id="is-their-a-unique-role-for-isavuconazole-vs.-other-triazoles" class="slide level2" data-background-image="bonemarrow.png">
<h2><br> <br> <br> <br> <br> Is their a unique role for isavuconazole <br> vs.&nbsp;other triazoles?</h2>
</section>
<section id="strong-opinions-about-voriconazole" class="slide level2">
<h2>Strong opinions about voriconazole</h2>

<img data-src="spec.png" class="quarto-figure quarto-figure-center r-stretch" width="800"></section>
<section id="pharmacokinetic-complexity-of-voriconazole" class="slide level2">
<h2>Pharmacokinetic complexity of voriconazole</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="voriconazole%20PK.png" class="quarto-figure quarto-figure-center"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="trifilio2014">(<a href="#/references" role="doc-biblioref" onclick="">Trifilio and Mehta 2014</a>)</span></p>
</div></aside></section>
<section id="triazole-toxicities" class="slide level2">
<h2>Triazole toxicities</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="triazole%20toxicity.png" class="quarto-figure quarto-figure-center"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="Lewis2011805 johnson2021">(<a href="#/references" role="doc-biblioref" onclick="">Lewis 2011</a>; <a href="#/references" role="doc-biblioref" onclick="">Johnson 2021</a>)</span></p>
</div></aside></section>
<section id="section-1" class="slide level2">
<h2></h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="new%20title.png" class="quarto-figure quarto-figure-center"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="ostrosky-zeichner2022J">(<a href="#/references" role="doc-biblioref" onclick="">Ostrosky-Zeichner et al. 2022</a>)</span></p>
</div></aside></section>
<section id="triazole-safety" class="slide level2">
<h2>Triazole safety</h2>
<p><br></p>
<ul>
<li class="fragment">Multicenter registry of prophylaxis (n=1777) and treatment (n=816) courses</li>
<li class="fragment">Adverse effects leading to treatment discontinuation:
<ul>
<li class="fragment">voriconazole (n=494) 14.2%</li>
<li class="fragment">posaconazole (n=547) 11.3%</li>
<li class="fragment"><strong>isavuconazole (n=514) 3.9%</strong></li>
<li class="fragment">multiple/sequenced therapy (n=454) 11.7%</li>
</ul></li>
<li class="fragment">QTc prolongation was rare, but more frequent with voriconazole and posaconazole</li>
<li class="fragment">Severe drug interactions occurred in 4% of all treated patients</li>
<li class="fragment">IFI mortality rates were similar for all agents ranging between 1.1-1.8%</li>
</ul>

<aside><div>
<p><span class="citation" data-cites="ostrosky-zeichner2022J">(<a href="#/references" role="doc-biblioref" onclick="">Ostrosky-Zeichner et al. 2022</a>)</span></p>
</div></aside></section>
<section id="what-makes-isavuconazole-isavuconazonium-unique" class="slide level2">
<h2>What makes isavuconazole <br>(isavuconazonium) unique?</h2>
<div class="columns">
<div class="column" style="width:40%;">
<p><br></p>
<div>
<div class="quarto-figure quarto-figure-left">
<figure>
<p><img data-src="isavuconazole.png" class="quarto-figure quarto-figure-left"></p>
</figure>
</div>
</div>
</div><div class="column" style="width:60%;">
<p><br></p>
<ul>
<li class="fragment">Broad spectrum of activity</li>
<li class="fragment">Prodrug IV/ oral formulations (&gt; 90% bioav.)</li>
<li class="fragment">Predictable linear PK, t<sub>1/2</sub>=130h</li>
<li class="fragment">Less need for TDM</li>
<li class="fragment">Better safety profile than voriconazole
<ul>
<li class="fragment">Less potent CYP3A4/5 inhibition</li>
<li class="fragment">Less cutaneous, CNS, hepatic toxicities</li>
<li class="fragment">Does not prolong QT</li>
</ul></li>
</ul>
</div>
</div>

<aside><div>
<p><span class="citation" data-cites="johnson2021 maertens2016">(<a href="#/references" role="doc-biblioref" onclick="">Johnson 2021</a>; <a href="#/references" role="doc-biblioref" onclick="">Maertens et al. 2016</a>)</span></p>
</div></aside></section>
<section id="qt-prolongation-risk-with-triazoles" class="slide level2">
<h2>QT prolongation risk with triazoles</h2>
<div class="columns">
<div class="column" style="width:40%;">
<p><br></p>
<p><img data-src="QTC.png" width="400"></p>
</div><div class="column" style="width:60%;">
<p><br></p>
<p><br></p>
<ul>
<li class="fragment">Older triazoles inhibit human ether-a-go-go (hERG) channel, which underlies rapid K<sup>+</sup> rectifier current</li>
<li class="fragment">Isavuconazole shortens cardiac QT in a dose-related manner, with no associated cardiac risk
<ul>
<li class="fragment">hCav1.2 L-type Ca<sup>++</sup> channels</li>
</ul></li>
</ul>
</div>
</div>

<aside><div>
<p><span class="citation" data-cites="keirns2017">(<a href="#/references" role="doc-biblioref" onclick="">Keirns et al. 2017</a>)</span></p>
</div></aside></section>
<section id="isavuconazole-versus-voriconazole-for-primary-treatment-of-invasive-mould-disease-caused-by-aspergillus-and-other-filamentous-fungi-secure" class="slide level2 smaller">
<h2>Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by <em>Aspergillus</em> and other filamentous fungi (SECURE)</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="Secure.png" class="quarto-figure quarto-figure-center" width="400"></p>
</figure>
</div>
<p><br></p>

<aside><div>
<p><span class="citation" data-cites="maertens2016">(<a href="#/references" role="doc-biblioref" onclick="">Maertens et al. 2016</a>)</span></p>
</div></aside></section>
<section id="treatment-emergent-adverse-effects-in-the-secure-trial" class="slide level2">
<h2>Treatment-emergent adverse effects <br> in the SECURE trial</h2>
<p><br></p>
<ul>
<li class="fragment"><strong>Overall drug-related AE (VOR-60% vs.&nbsp;ISA-42%, p&lt;0.001)</strong>
<ul>
<li class="fragment"><p>Hepatobiliary disorders (VOR-16% vs.&nbsp;ISA-9%, p=0.016)</p></li>
<li class="fragment"><p>Visual disturbances (VOR-27% vs.&nbsp;ISA-15%, p=0.002)</p></li>
<li class="fragment"><p>Skin or subcutaneous tissue (VOR-42% vs.&nbsp;ISA-33%, p=0.037</p></li>
</ul></li>
</ul>

<aside><div>
<p><span class="citation" data-cites="maertens2016">(<a href="#/references" role="doc-biblioref" onclick="">Maertens et al. 2016</a>)</span></p>
</div></aside></section>
<section id="isavuconazole-treatment-for-mucormycosis-a-single-arm-open-label-case-control-study-vital" class="slide level2">
<h2>Isavuconazole treatment for mucormycosis: <br> a single-arm, open-label, case-control study (VITAL)</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="isavuconazole_Mucor.png" class="quarto-figure quarto-figure-center" width="600"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="marty2014">(<a href="#/references" role="doc-biblioref" onclick="">Marty et al. 2014</a>)</span></p>
</div></aside></section>
<section id="isavuconazole-drug-interaction-potential-in-hsct" class="slide level2">
<h2>Isavuconazole drug interaction potential in HSCT</h2>
<p><br></p>
<table style="width:100%;">
<colgroup>
<col style="width: 14%">
<col style="width: 20%">
<col style="width: 64%">
</colgroup>
<thead>
<tr class="header">
<th>Drug</th>
<th>Pharmacokinetic change</th>
<th>Initial management</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Tacrolimus</strong></td>
<td><p>↑ AUC 1.8-3xfold</p>
<p>↑ C<sub>max</sub> 1.4-2.8xfold</p></td>
<td>40-50% reduction in tacrolimus dose, TDM. <br>Some case series suggest no empiric dose reduction was required</td>
</tr>
<tr class="even">
<td><strong>Prednisone or Prednisolone</strong></td>
<td>↑ AUC (8%) minimal</td>
<td>No dose adjustments recommended</td>
</tr>
<tr class="odd">
<td><strong>Ruxolitinib</strong></td>
<td>↑AUC and C<sub>max</sub> by an average of 27% and 8%</td>
<td>Although dose reduction is recommended for strong CYP3A4 inhibitors, no dose reduction recommended with moderate inhibitors such as isavuconazole</td>
</tr>
</tbody>
</table>

<aside><div>
<p><span class="citation" data-cites="kufel2018 kieu2019 groll2017b ouatas2017">(<a href="#/references" role="doc-biblioref" onclick="">Kufel et al. 2018</a>; <a href="#/references" role="doc-biblioref" onclick="">Kieu et al. 2019</a>; <a href="#/references" role="doc-biblioref" onclick="">Groll et al. 2017</a>; <a href="#/references" role="doc-biblioref" onclick="">Ouatas et al. 2017</a>)</span></p>
</div></aside></section>
<section id="isavuconazole-drug-interaction-potential" class="slide level2">
<h2>Isavuconazole drug interaction potential</h2>
<p><br></p>
<table style="width:99%;">
<colgroup>
<col style="width: 13%">
<col style="width: 18%">
<col style="width: 67%">
</colgroup>
<thead>
<tr class="header">
<th>Drug</th>
<th>Pharmacokinetic change</th>
<th>Initial management</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Venetoclax</strong></td>
<td>↑AUC 2-3.9xfold</td>
<td>Dose reduction of venetoclax by 50%</td>
</tr>
<tr class="even">
<td><strong>Midostaurin</strong></td>
<td>↑AUC 1.44xfold higher</td>
<td>Avoid strong CYP3A4 inhibitors, no dose reduction recommended for moderate CYP3A4 inhibitors</td>
</tr>
<tr class="odd">
<td><strong>Gilteritinib</strong></td>
<td><p>↑AUC 1.4xfold; <br></p>
<p>↑C<sub>max</sub> 1.2-fold higher</p></td>
<td>Avoid strong CYP3A4 inhibitors, no dose reduction recommended for moderate CYP3A4 inhibitors</td>
</tr>
</tbody>
</table>

<aside><div>
<p><span class="citation" data-cites="kufel2018 kieu2019 groll2017b ouatas2017">(<a href="#/references" role="doc-biblioref" onclick="">Kufel et al. 2018</a>; <a href="#/references" role="doc-biblioref" onclick="">Kieu et al. 2019</a>; <a href="#/references" role="doc-biblioref" onclick="">Groll et al. 2017</a>; <a href="#/references" role="doc-biblioref" onclick="">Ouatas et al. 2017</a>)</span></p>
</div></aside></section>
<section id="does-tdm-support-claims-of-less-potent-cyp3a4-inhibition" class="slide level2">
<h2>Does TDM support claims of less potent <br> CYP3A4 inhibition?</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="Menna_midostraurin.png" class="quarto-figure quarto-figure-center"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="Menna2021-mb">(<a href="#/references" role="doc-biblioref" onclick="">Menna et al. 2021</a>)</span></p>
</div></aside></section>
<section id="section-2" class="slide level2">
<h2></h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="Bose%20study.png" class="quarto-figure quarto-figure-center"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="bose2020">(<a href="#/references" role="doc-biblioref" onclick="">Bose et al. 2020</a>)</span></p>
</div></aside></section>
<section id="section-3" class="slide level2">
<h2></h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="bose_study.png" class="quarto-figure quarto-figure-center"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="bose2020">(<a href="#/references" role="doc-biblioref" onclick="">Bose et al. 2020</a>)</span></p>
</div></aside></section>
<section id="section-4" class="slide level2">
<h2></h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="bose3.png" class="quarto-figure quarto-figure-center"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="bose2020">(<a href="#/references" role="doc-biblioref" onclick="">Bose et al. 2020</a>)</span></p>
</div></aside></section>
<section id="section-5" class="slide level2">
<h2></h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="bose4.png" class="quarto-figure quarto-figure-center"></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="bose2020">(<a href="#/references" role="doc-biblioref" onclick="">Bose et al. 2020</a>)</span></p>
</div></aside></section>
<section id="isavuconazole-tolerability" class="slide level2">
<h2>Isavuconazole tolerability</h2>
<p><br></p>
<p><br></p>
<div class="columns">
<div class="column" style="width:50%;">
<ul>
<li class="fragment"><strong>Posaconazole experience</strong> <br> <strong>(previous study with tablet/IV)</strong>
<ul>
<li class="fragment"><p><span style="color:red;">Grade III/IV liver injury with tablet and IV formulations (9%)</span></p></li>
<li class="fragment"><p>Primary hyperbilirubinemia</p></li>
<li class="fragment"><p>Higher frequency in patients with POS serum levels &gt; 1,830 ng/mL</p></li>
</ul></li>
</ul>
</div><div class="column" style="width:50%;">
<ul>
<li class="fragment"><strong>Isavuconazole (current study)</strong>
<ul>
<li class="fragment"><p><span style="color:red;">Grade 1 transaminitis (2.7%)</span></p></li>
<li class="fragment"><p>Grade 2 elevated T. bilirubin (1.3%)</p></li>
<li class="fragment"><p>No elevations in QTc detected vs.&nbsp;baselines at 10 days</p></li>
</ul></li>
</ul>
</div><div class="fragment">
<p>“Isavuconazole was well tolerated and facilitated use of the most potent molecular-targeted agents in remission-induction chemotherapy with excellent short term survival and high remission rates.”</p>
</div>
</div>

<aside><div>
<p><span class="citation" data-cites="bose2020 Tverdek2017-gh">(<a href="#/references" role="doc-biblioref" onclick="">Bose et al. 2020</a>; <a href="#/references" role="doc-biblioref" onclick="">Tverdek et al. 2017</a>)</span></p>
</div></aside></section>
<section id="dd" class="slide level2">
<h2>dd</h2>

<img data-src="bose5.png" class="quarto-figure quarto-figure-center r-stretch"><p><br></p>
<p><br></p>
<div>
<p><span class="citation" data-cites="Young2021-jx">(<a href="#/references" role="doc-biblioref" onclick="">Young 2021</a>)</span></p>
</div>
</section>
<section id="jo-anne-h.-young-clin-infect-dis-2021" class="slide level2">
<h2>Jo-Anne H. Young, <em>Clin Infect Dis 2021</em></h2>
<p><br></p>
<p><br></p>
<div class="fragment">
<p>“This is the first antifungal prophylaxis study in this select population of patients with leukemia, specifically, those patients being treated with the BCL-2 antagonist venetoclax and fms3-like tyrosine kinase 3 (FLT3) inhibitors.</p>
</div>
<p><br></p>
<div class="fragment">
<p>“Clinicians should take away from these studies the fact that many of the advanced-generation azoles can be used interchangeably in times of prophylaxis when they are needed.”</p>
</div>
</section>
<section id="summary" class="slide level2" data-background-image="bonemarrow.png">
<h2>Summary</h2>
<p><br></p>
<ul>
<li class="fragment"><strong>Knowledge of fungal infection risk with targeted therapy is evolving, and depends heavily on the individual patient treatment scenario</strong> <br></li>
<li class="fragment"><strong>Many small molecule inhibitors are metabolised by CYP3A4/5 and have potential for QTc prolongation, making concurrent use with broad-spectrum triazoles difficult</strong> <br></li>
<li class="fragment"><strong>Isavuconazole has several unique pharmacokinetic and safety advantages over older triazoles, making it an useful alternative in patients receiving targeted therapies</strong></li>
</ul>
</section>
<section id="thank-you-for-your-attention" class="slide level2">
<h2>Thank you for your attention!</h2>
<p><img data-src="bologna%202.png" class="absolute" style="top: 200px; left: 0px; width: 442px; height: 303px; "></p>
<p><img data-src="bologna3.png" class="absolute" style="top: 50px; right: 50px; width: 450px; height: 250px; "></p>
<p><img data-src="Screenshot%202022-05-16%20at%2012.30.29.png" class="absolute" style="bottom: 0px; right: 50px; width: 418px; height: 273px; "></p>
</section>
<section id="references" class="slide level2 smaller scrollable">
<h2>References</h2>
<p><br></p>
<p>All figures created by R. Lewis using www.biorender.com <br> <br></p>
<div class="quarto-auto-generated-content">
<div class="footer footer-default">

</div>
</div>
<div id="refs" class="references csl-bib-body hanging-indent" data-entry-spacing="0" role="list">
<div id="ref-andes2016" class="csl-entry" role="listitem">
Andes, David, Nkechi Azie, Hongbo Yang, Rachel Harrington, Caroline Kelley, Ruo-Ding Tan, Eric Q Wu, et al. 2016. <span>“Drug-<span>Drug Interaction Associated</span> with <span>Mold-Active Triazoles</span> Among <span>Hospitalized Patients</span>.”</span> <em>Antimicrobial Agents and Chemotherapy</em> 60 (6): 3398–3406. <a href="https://doi.org/10.1128/AAC.00054-16">https://doi.org/10.1128/AAC.00054-16</a>.
</div>
<div id="ref-bhatnagar2021J" class="csl-entry" role="listitem">
Bhatnagar, Sumit, Dwaipayan Mukherjee, Ahmed Hamed Salem, Dale Miles, Rajeev M. Menon, and John P. Gibbs. 2021. <span>“Dose Adjustment of Venetoclax When Co-Administered with Posaconazole: Clinical Drug-Drug Interaction Predictions Using a <span>PBPK</span> Approach.”</span> <em>Cancer Chemotherapy and Pharmacology</em> 87 (4): 465–74. <a href="https://doi.org/10.1007/s00280-020-04179-w">https://doi.org/10.1007/s00280-020-04179-w</a>.
</div>
<div id="ref-bose2020" class="csl-entry" role="listitem">
Bose, Prithviraj, David McCue, Sebastian Wurster, Nathan P Wiederhold, Marina Konopleva, Tapan M Kadia, Gautam Borthakur, et al. 2020. <span>“Isavuconazole as <span>Primary Anti-Fungal Prophylaxis</span> in <span>Patients</span> with <span>Acute Myeloid Leukemia</span> or <span>Myelodysplastic Syndrome</span>: <span>An Open-Label</span>, <span>Prospective</span>, <span>Phase II Study</span>.”</span> <em>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</em>, April. <a href="https://doi.org/10.1093/cid/ciaa358">https://doi.org/10.1093/cid/ciaa358</a>.
</div>
<div id="ref-bruggemann2009a" class="csl-entry" role="listitem">
Brüggemann, Roger J. M., Jan-Willem C. Alffenaar, Nicole M. A. Blijlevens, Eliane M. Billaud, Jos G. W. Kosterink, Paul E. Verweij, David M. Burger, and Louis D. Saravolatz. 2009. <span>“Clinical <span>Relevance</span> of the <span>Pharmacokinetic Interactions</span> of <span>Azole Antifungal Drugs</span> with <span>Other Coadministered Agents</span>.”</span> <em>Clinical Infectious Diseases</em> 48 (10): 1441–58. <a href="https://doi.org/10.1086/598327">https://doi.org/10.1086/598327</a>.
</div>
<div id="ref-bruggemann2022" class="csl-entry" role="listitem">
Brüggemann, Roger J, Rebecca Verheggen, Emmy Boerrigter, Marta Stanzani, Paul E Verweij, Nicole M A Blijlevens, and Russell E Lewis. 2022. <span>“Management of Drugdrug Interactions of Targeted Therapies for Haematological Malignancies and Triazole Antifungal Drugs.”</span> <em>The Lancet Haematology</em> 9 (1): e58–72. <a href="https://doi.org/10.1016/S2352-3026(21)00232-5">https://doi.org/10.1016/S2352-3026(21)00232-5</a>.
</div>
<div id="ref-burger2015" class="csl-entry" role="listitem">
Burger, Jan A, Alessandra Tedeschi, Paul M Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Osnat Bairey, et al. 2015. <span>“Ibrutinib as <span>Initial Therapy</span> for <span>Patients</span> with <span>Chronic Lymphocytic Leukemia</span>.”</span> <em>The New England Journal of Medicine</em> 373 (25): 2425–37. <a href="https://doi.org/10.1056/NEJMoa1509388">https://doi.org/10.1056/NEJMoa1509388</a>.
</div>
<div id="ref-chamilos2018" class="csl-entry" role="listitem">
Chamilos, Georgios, Michail S Lionakis, and Dimitrios P Kontoyiannis. 2018. <span>“Call for <span>Action</span>: <span>Invasive Fungal Infections Associated With Ibrutinib</span> and <span>Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways</span>.”</span> <em>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</em> 66 (1): 140–48. <a href="https://doi.org/10.1093/cid/cix687">https://doi.org/10.1093/cid/cix687</a>.
</div>
<div id="ref-desai2024" class="csl-entry" role="listitem">
Desai, Jigar V., Marissa A. Zarakas, Andrew L. Wishart, Mark Roschewski, Mariano A. Aufiero, Ágnes Donkó, Gustaf Wigerblad, et al. 2024. <span>“BTK Drives Neutrophil Activation for Sterilizing Antifungal Immunity.”</span> <em>The Journal of Clinical Investigation</em>, May. <a href="https://doi.org/10.1172/JCI176142">https://doi.org/10.1172/JCI176142</a>.
</div>
<div id="ref-frei2020J" class="csl-entry" role="listitem">
Frei, Michael, Samuel L. Aitken, Nitin Jain, Philip Thompson, William Wierda, Dimitrios P. Kontoyiannis, and Adam J. DiPippo. 2020. <span>“Incidence and Characterization of Fungal Infections in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib.”</span> <em>Leukemia &amp; Lymphoma</em> 61 (10): 2488–91. <a href="https://doi.org/10.1080/10428194.2020.1775215">https://doi.org/10.1080/10428194.2020.1775215</a>.
</div>
<div id="ref-ghez2018" class="csl-entry" role="listitem">
Ghez, David, Anne Calleja, Caroline Protin, Marine Baron, Marie-Pierre Ledoux, Gandhi Damaj, Mathieu Dupont, et al. 2018. <span>“Early-Onset Invasive Aspergillosis and Other Fungal Infections in Patients Treated with Ibrutinib.”</span> <em>Blood</em> 131 (17): 1955–59. <a href="https://doi.org/10.1182/blood-2017-11-818286">https://doi.org/10.1182/blood-2017-11-818286</a>.
</div>
<div id="ref-gomes2014" class="csl-entry" role="listitem">
Gomes, Marisa Z R, Ying Jiang, Victor E Mulanovich, Russell E Lewis, and Dimitrios P Kontoyiannis. 2014. <span>“Effectiveness of Primary Anti-<span>Aspergillus</span> Prophylaxis During Remission Induction Chemotherapy of Acute Myeloid Leukemia.”</span> <em>Antimicrobial Agents and Chemotherapy</em> 58 (5): 2775–80. <a href="https://doi.org/10.1128/AAC.01527-13">https://doi.org/10.1128/AAC.01527-13</a>.
</div>
<div id="ref-groll2017b" class="csl-entry" role="listitem">
Groll, A H, A Desai, D Han, C Howieson… - … in drug development, and 2017. 2017. <span>“Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole with the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone ….”</span> <em>Wiley Online Library</em>.
</div>
<div id="ref-herbst2015" class="csl-entry" role="listitem">
Herbst, Susanne, Anand Shah, Maria Mazon Moya, Vanessa Marzola, Barbara Jensen, Anna Reed, Mark A Birrell, et al. 2015. <span>“Phagocytosis-Dependent Activation of a TLR9<span></span>BTK<span></span>calcineurin<span></span>NFAT Pathway Co-Ordinates Innate Immunity to Aspergillus Fumigatus.”</span> <em>EMBO Molecular Medicine</em> 7 (3): 240–58. <a href="https://doi.org/10.15252/emmm.201404556">https://doi.org/10.15252/emmm.201404556</a>.
</div>
<div id="ref-johnson2021" class="csl-entry" role="listitem">
Johnson, Melissa D. 2021. <span>“Antifungals in <span>Clinical Use</span> and the <span>Pipeline</span>.”</span> <em>Infectious Disease Clinics of North America</em>, Fungal <span>Infections</span>, 35 (2): 341–71. <a href="https://doi.org/10.1016/j.idc.2021.03.005">https://doi.org/10.1016/j.idc.2021.03.005</a>.
</div>
<div id="ref-kantarjian2022J" class="csl-entry" role="listitem">
Kantarjian, Hagop M., Nitin Jain, Guillermo Garcia-Manero, Mary Alma Welch, Farhad Ravandi, William G. Wierda, and Elias J. Jabbour. 2022. <span>“The Cure of Leukemia Through the Optimist’s Prism.”</span> <em>Cancer</em> 128 (2): 240–59. <a href="https://doi.org/10.1002/cncr.33933">https://doi.org/10.1002/cncr.33933</a>.
</div>
<div id="ref-kantarjian2021" class="csl-entry" role="listitem">
Kantarjian, Hagop, Nicholas J Short, Courtney DiNardo, Eytan M Stein, Naval Daver, Alexander E Perl, Eunice S Wang, Andrew Wei, and Martin Tallman. 2021. <span>“Harnessing the Benefits of Available Targeted Therapies in Acute Myeloid Leukaemia.”</span> <em>The Lancet Haematology</em> 8 (12): e922–33. <a href="https://doi.org/10.1016/S2352-3026(21)00270-2">https://doi.org/10.1016/S2352-3026(21)00270-2</a>.
</div>
<div id="ref-keirns2017" class="csl-entry" role="listitem">
Keirns, J, A Desai, D Kowalski, C Lademacher, S Mujais, B Parker, M J Schneidkraut, et al. 2017. <span>“<span>QT Interval Shortening With Isavuconazole</span>: <span>In Vitro</span> and <span>In Vivo Effects</span> on <span>Cardiac Repolarization</span>.”</span> <em>Clinical Pharmacology and Therapeutics</em> 101 (6): 782–90. <a href="https://doi.org/10.1002/cpt.620">https://doi.org/10.1002/cpt.620</a>.
</div>
<div id="ref-kieu2019" class="csl-entry" role="listitem">
Kieu, Van, Kristi Jhangiani, Sanjeet Dadwal, Ryotaro Nakamura, and Doreen Pon. 2019. <span>“Effect of Isavuconazole on Tacrolimus and Sirolimus Serum Concentrations in Allogeneic Hematopoietic Stem Cell Transplant Patients: <span>A</span> Drug-Drug Interaction Study.”</span> <em>Transplant Infectious Disease: An Official Journal of the Transplantation Society</em> 21 (1): e13007. <a href="https://doi.org/10.1111/tid.13007">https://doi.org/10.1111/tid.13007</a>.
</div>
<div id="ref-kufel2018" class="csl-entry" role="listitem">
Kufel, Wesley D, Paul M Armistead, Lindsay M Daniels, Jonathan R Ptachcinski, Maurice D Alexander, and J Ryan Shaw. 2018. <span>“Drug-<span>Drug Interaction Between Isavuconazole</span> and <span>Tacrolimus</span>: <span>Is Empiric Dose Adjustment Necessary</span>?”</span> <em>Journal of Pharmacy Practice</em>, July, 897190018790688. <a href="https://doi.org/10.1177/0897190018790688">https://doi.org/10.1177/0897190018790688</a>.
</div>
<div id="ref-Lewis2011805" class="csl-entry" role="listitem">
Lewis, R. E. 2011. <span>“Current Concepts in Antifungal Pharmacology.”</span> <em>Mayo Clinic Proceedings</em> 86 (8): 805–17. <a href="https://doi.org/10.4065/mcp.2011.0247">https://doi.org/10.4065/mcp.2011.0247</a>.
</div>
<div id="ref-maertens2016" class="csl-entry" role="listitem">
Maertens, Johan A, Issam I Raad, Kieren A Marr, Thomas F Patterson, Dimitrios P Kontoyiannis, Oliver A Cornely, Eric J Bow, et al. 2016. <span>“Isavuconazole Versus Voriconazole for Primary Treatment of Invasive Mould Disease Caused by <span>Aspergillus</span> and Other Filamentous Fungi (<span>SECURE</span>): A Phase 3, Randomised-Controlled, Non-Inferiority Trial.”</span> <em>The Lancet</em> 387 (10020): 760–69. <a href="https://doi.org/10.1016/S0140-6736(15)01159-9">https://doi.org/10.1016/S0140-6736(15)01159-9</a>.
</div>
<div id="ref-marty2014" class="csl-entry" role="listitem">
Marty, Francisco M, John R Perfect, Oliver A Cornely, Kathleen Mullane, Galia Rahav, Misun Lee, Masanori Ito, Rochelle Maher, Bernhardt Zeiher, and Luis Ostrosky-Zeichner. 2014. <span>“An Open-Label Phase 3 Study of Isavuconazole (<span>VITAL</span>): <span>Focus</span> on Mucormycosis.”</span> <em>Risk</em> 8: 21–26.
</div>
<div id="ref-megias-vericat2020J" class="csl-entry" role="listitem">
Megías-Vericat, Juan Eduardo, Antonio Solana-Altabella, Octavio Ballesta-López, David Martínez-Cuadrón, and Pau Montesinos. 2020. <span>“Drug-Drug Interactions of Newly Approved Small Molecule Inhibitors for Acute Myeloid Leukemia.”</span> <em>Annals of Hematology</em> 99 (9): 1989–2007. <a href="https://doi.org/10.1007/s00277-020-04186-0">https://doi.org/10.1007/s00277-020-04186-0</a>.
</div>
<div id="ref-Menna2021-mb" class="csl-entry" role="listitem">
Menna, Pierantonio, Emanuela Salvatorelli, Maria Ilaria Del Principe, Salvatore Perrone, Livio Pagano, Francesco Marchesi, and Giorgio Minotti. 2021. <span>“Choosing Antifungals for the <span>Midostaurin-Treated</span> Patient: <span>Does CYP3A4</span> Outweigh Recommendations? <span>A</span> Brief Insight from Real Life.”</span> <em>Chemotherapy</em> 66 (1-2): 47–52. <a href="https://doi.org/10.1159/000513989">https://doi.org/10.1159/000513989</a>.
</div>
<div id="ref-ostrosky-zeichner2022J" class="csl-entry" role="listitem">
Ostrosky-Zeichner, L., M. H. Nguyen, J. Bubalo, B. D. Alexander, M. H. Miceli, P. G. Pappas, J. Jiang, Y. Song, and G. R. Thompson. 2022. <span>“Multicenter <span>Registry</span> of <span>Patients Receiving Systemic Mold-Active Triazoles</span> for the <span>Management</span> of <span>Invasive Fungal Infections</span>.”</span> <em>Infectious Diseases and Therapy</em>, June. <a href="https://doi.org/10.1007/s40121-022-00661-5">https://doi.org/10.1007/s40121-022-00661-5</a>.
</div>
<div id="ref-ouatas2017" class="csl-entry" role="listitem">
Ouatas, Taoufik, Vincent Duval, Karen Sinclair, and Noah Berkowitz. 2017. <span>“Concomitant <span>Use</span> of <span>Midostaurin</span> with <span>Strong CYP3A4 Inhibitors</span>: <span>An Analysis</span> from the <span>Ratify Trial</span>.”</span> <em>Blood</em> 130 (Supplement 1): 3814–14. <a href="https://doi.org/10.1182/blood.V130.Suppl_1.3814.3814">https://doi.org/10.1182/blood.V130.Suppl_1.3814.3814</a>.
</div>
<div id="ref-rausch2019" class="csl-entry" role="listitem">
Rausch, Caitlin R, Courtney D DiNardo, Abhishek Maiti, Nadya Jammal, Tapan M Kadia, Kayleigh Marx, Gautam M Borthakur, et al. 2019. <span>“Venetoclax Dosing in Combination with Antifungal Agents: <span>Real</span> World Experience in Patients with Acute Myeloid Leukemia.”</span> <em>Blood</em> 134 (Supplement_1): 2640–40. <a href="https://doi.org/10.1182/blood-2019-131988">https://doi.org/10.1182/blood-2019-131988</a>.
</div>
<div id="ref-stemler2022J" class="csl-entry" role="listitem">
Stemler, Jannik, Nick de Jonge, Nicole Skoetz, János Sinkó, Roger J Brüggemann, Alessandro Busca, Ronen Ben-Ami, et al. 2022. <span>“Antifungal Prophylaxis in Adult Patients with Acute Myeloid Leukaemia Treated with Novel Targeted Therapies: A Systematic Review and Expert Consensus Recommendation from the <span>European Hematology Association</span>.”</span> <em>The Lancet Haematology</em> 9 (5): e361–73. <a href="https://doi.org/10.1016/S2352-3026(22)00073-4">https://doi.org/10.1016/S2352-3026(22)00073-4</a>.
</div>
<div id="ref-trifilio2014" class="csl-entry" role="listitem">
Trifilio, S, and J Mehta. 2014. <span>“Antimicrobial Prophylaxis in Hematopoietic Stem Cell Transplantation Recipients: 10 Years After.”</span> <em>Transplant Infectious Disease: An Official Journal of the Transplantation Society</em> 16 (4): 548–55. <a href="https://doi.org/10.1111/tid.12237">https://doi.org/10.1111/tid.12237</a>.
</div>
<div id="ref-Tverdek2017-gh" class="csl-entry" role="listitem">
Tverdek, Frank P, Sang Taek Heo, Samuel L Aitken, Bruno Granwehr, and Dimitrios P Kontoyiannis. 2017. <span>“Real-<span>Life</span> Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.”</span> <em>Antimicrobial Agents and Chemotherapy</em> 61 (8). <a href="https://doi.org/10.1128/AAC.00188-17">https://doi.org/10.1128/AAC.00188-17</a>.
</div>
<div id="ref-varughese2018" class="csl-entry" role="listitem">
Varughese, Tilly, Ying Taur, Nina Cohen, M Lia Palomba, Susan K Seo, Tobias M Hohl, and Gil Redelman-Sidi. 2018. <span>“Serious <span>Infections</span> in <span>Patients Receiving Ibrutinib</span> for <span>Treatment</span> of <span>Lymphoid Cancer</span>.”</span> <em>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</em> 67 (5): 687–92. <a href="https://doi.org/10.1093/cid/ciy175">https://doi.org/10.1093/cid/ciy175</a>.
</div>
<div id="ref-wang2020a" class="csl-entry" role="listitem">
Wang, Eunice S, and Jeffrey Baron. 2020. <span>“Management of Toxicities Associated with Targeted Therapies for Acute Myeloid Leukemia: When to Push Through and When to Stop.”</span> <em>Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program</em> 2020 (1): 57–66. <a href="https://doi.org/10.1182/hematology.2020000089">https://doi.org/10.1182/hematology.2020000089</a>.
</div>
<div id="ref-Young2021-jx" class="csl-entry" role="listitem">
Young, Jo-Anne H. 2021. <span>“Both <span>‘<span>Small Ball</span>’</span> and <span>‘<span>Big</span> Inning’</span> Teams Are Progressing the Value of Antifungal Prophylaxis Among Patients with Hematologic Malignancy.”</span> <em>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</em> 72 (10): 1764–66. <a href="https://doi.org/10.1093/cid/ciaa569">https://doi.org/10.1093/cid/ciaa569</a>.
</div>
</div>
</section>

    </div>
  </div>

  <script>window.backupDefine = window.define; window.define = undefined;</script>
  <script src="avir talk_files/libs/revealjs/dist/reveal.js"></script>
  <!-- reveal.js plugins -->
  <script src="avir talk_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.js"></script>
  <script src="avir talk_files/libs/revealjs/plugin/pdf-export/pdfexport.js"></script>
  <script src="avir talk_files/libs/revealjs/plugin/reveal-menu/menu.js"></script>
  <script src="avir talk_files/libs/revealjs/plugin/reveal-menu/quarto-menu.js"></script>
  <script src="avir talk_files/libs/revealjs/plugin/multiplex/socket.io.js"></script>
  <script src="avir talk_files/libs/revealjs/plugin/multiplex/multiplex.js"></script>
  <script src="avir talk_files/libs/revealjs/plugin/quarto-support/support.js"></script>
  

  <script src="avir talk_files/libs/revealjs/plugin/notes/notes.js"></script>
  <script src="avir talk_files/libs/revealjs/plugin/search/search.js"></script>
  <script src="avir talk_files/libs/revealjs/plugin/zoom/zoom.js"></script>
  <script src="avir talk_files/libs/revealjs/plugin/math/math.js"></script>
  <script>window.define = window.backupDefine; window.backupDefine = undefined;</script>

  <script>

      // Full list of configuration options available at:
      // https://revealjs.com/config/
      Reveal.initialize({
'controlsAuto': false,
'previewLinksAuto': false,
'pdfSeparateFragments': false,
'autoAnimateEasing': "ease",
'autoAnimateDuration': 1,
'autoAnimateUnmatched': true,
'menu': {"side":"left","useTextContentForMissingTitles":true,"markers":false,"loadIcons":false,"custom":[{"title":"Tools","icon":"<i class=\"fas fa-gear\"></i>","content":"<ul class=\"slide-menu-items\">\n<li class=\"slide-tool-item active\" data-item=\"0\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.fullscreen(event)\"><kbd>f</kbd> Fullscreen</a></li>\n<li class=\"slide-tool-item\" data-item=\"1\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.speakerMode(event)\"><kbd>s</kbd> Speaker View</a></li>\n<li class=\"slide-tool-item\" data-item=\"2\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.overview(event)\"><kbd>o</kbd> Slide Overview</a></li>\n<li class=\"slide-tool-item\" data-item=\"3\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.togglePdfExport(event)\"><kbd>e</kbd> PDF Export Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"4\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.keyboardHelp(event)\"><kbd>?</kbd> Keyboard Help</a></li>\n</ul>"}],"openButton":true},
'multiplex': {"secret":"16526959727685265603","id":"438e2edb09a49c62","url":"https://reveal-multiplex.glitch.me/"},
'smaller': false,
 
        // Display controls in the bottom right corner
        controls: true,

        // Help the user learn the controls by providing hints, for example by
        // bouncing the down arrow when they first encounter a vertical slide
        controlsTutorial: false,

        // Determines where controls appear, "edges" or "bottom-right"
        controlsLayout: 'edges',

        // Visibility rule for backwards navigation arrows; "faded", "hidden"
        // or "visible"
        controlsBackArrows: 'faded',

        // Display a presentation progress bar
        progress: true,

        // Display the page number of the current slide
        slideNumber: false,

        // 'all', 'print', or 'speaker'
        showSlideNumber: 'all',

        // Add the current slide number to the URL hash so that reloading the
        // page/copying the URL will return you to the same slide
        hash: true,

        // Start with 1 for the hash rather than 0
        hashOneBasedIndex: false,

        // Flags if we should monitor the hash and change slides accordingly
        respondToHashChanges: true,

        // Push each slide change to the browser history
        history: true,

        // Enable keyboard shortcuts for navigation
        keyboard: true,

        // Enable the slide overview mode
        overview: true,

        // Disables the default reveal.js slide layout (scaling and centering)
        // so that you can use custom CSS layout
        disableLayout: false,

        // Vertical centering of slides
        center: false,

        // Enables touch navigation on devices with touch input
        touch: true,

        // Loop the presentation
        loop: false,

        // Change the presentation direction to be RTL
        rtl: false,

        // see https://revealjs.com/vertical-slides/#navigation-mode
        navigationMode: 'linear',

        // Randomizes the order of slides each time the presentation loads
        shuffle: false,

        // Turns fragments on and off globally
        fragments: true,

        // Flags whether to include the current fragment in the URL,
        // so that reloading brings you to the same fragment position
        fragmentInURL: false,

        // Flags if the presentation is running in an embedded mode,
        // i.e. contained within a limited portion of the screen
        embedded: false,

        // Flags if we should show a help overlay when the questionmark
        // key is pressed
        help: true,

        // Flags if it should be possible to pause the presentation (blackout)
        pause: true,

        // Flags if speaker notes should be visible to all viewers
        showNotes: false,

        // Global override for autoplaying embedded media (null/true/false)
        autoPlayMedia: null,

        // Global override for preloading lazy-loaded iframes (null/true/false)
        preloadIframes: null,

        // Number of milliseconds between automatically proceeding to the
        // next slide, disabled when set to 0, this value can be overwritten
        // by using a data-autoslide attribute on your slides
        autoSlide: 0,

        // Stop auto-sliding after user input
        autoSlideStoppable: true,

        // Use this method for navigation when auto-sliding
        autoSlideMethod: null,

        // Specify the average time in seconds that you think you will spend
        // presenting each slide. This is used to show a pacing timer in the
        // speaker view
        defaultTiming: null,

        // Enable slide navigation via mouse wheel
        mouseWheel: false,

        // The display mode that will be used to show slides
        display: 'block',

        // Hide cursor if inactive
        hideInactiveCursor: true,

        // Time before the cursor is hidden (in ms)
        hideCursorTime: 5000,

        // Opens links in an iframe preview overlay
        previewLinks: false,

        // Transition style (none/fade/slide/convex/concave/zoom)
        transition: 'fade',

        // Transition speed (default/fast/slow)
        transitionSpeed: 'fast',

        // Transition style for full page slide backgrounds
        // (none/fade/slide/convex/concave/zoom)
        backgroundTransition: 'none',

        // Number of slides away from the current that are visible
        viewDistance: 3,

        // Number of slides away from the current that are visible on mobile
        // devices. It is advisable to set this to a lower number than
        // viewDistance in order to save resources.
        mobileViewDistance: 2,

        // The "normal" size of the presentation, aspect ratio will be preserved
        // when the presentation is scaled to fit different resolutions. Can be
        // specified using percentage units.
        width: 1050,

        height: 700,

        // Factor of the display size that should remain empty around the content
        margin: 0.1,

        math: {
          mathjax: 'https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.0/MathJax.js',
          config: 'TeX-AMS_HTML-full',
          tex2jax: {
            inlineMath: [['\\(','\\)']],
            displayMath: [['\\[','\\]']],
            balanceBraces: true,
            processEscapes: false,
            processRefs: true,
            processEnvironments: true,
            preview: 'TeX',
            skipTags: ['script','noscript','style','textarea','pre','code'],
            ignoreClass: 'tex2jax_ignore',
            processClass: 'tex2jax_process'
          },
        },

        // reveal.js plugins
        plugins: [QuartoLineHighlight, PdfExport, RevealMenu, QuartoSupport,

          RevealMath,
          RevealNotes,
          RevealSearch,
          RevealZoom
        ]
      });
    </script>
    <script id="quarto-html-after-body" type="application/javascript">
    window.document.addEventListener("DOMContentLoaded", function (event) {
      const toggleBodyColorMode = (bsSheetEl) => {
        const mode = bsSheetEl.getAttribute("data-mode");
        const bodyEl = window.document.querySelector("body");
        if (mode === "dark") {
          bodyEl.classList.add("quarto-dark");
          bodyEl.classList.remove("quarto-light");
        } else {
          bodyEl.classList.add("quarto-light");
          bodyEl.classList.remove("quarto-dark");
        }
      }
      const toggleBodyColorPrimary = () => {
        const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
        if (bsSheetEl) {
          toggleBodyColorMode(bsSheetEl);
        }
      }
      toggleBodyColorPrimary();  
      const tabsets =  window.document.querySelectorAll(".panel-tabset-tabby")
      tabsets.forEach(function(tabset) {
        const tabby = new Tabby('#' + tabset.id);
      });
      const isCodeAnnotation = (el) => {
        for (const clz of el.classList) {
          if (clz.startsWith('code-annotation-')) {                     
            return true;
          }
        }
        return false;
      }
      const clipboard = new window.ClipboardJS('.code-copy-button', {
        text: function(trigger) {
          const codeEl = trigger.previousElementSibling.cloneNode(true);
          for (const childEl of codeEl.children) {
            if (isCodeAnnotation(childEl)) {
              childEl.remove();
            }
          }
          return codeEl.innerText;
        }
      });
      clipboard.on('success', function(e) {
        // button target
        const button = e.trigger;
        // don't keep focus
        button.blur();
        // flash "checked"
        button.classList.add('code-copy-button-checked');
        var currentTitle = button.getAttribute("title");
        button.setAttribute("title", "Copied!");
        let tooltip;
        if (window.bootstrap) {
          button.setAttribute("data-bs-toggle", "tooltip");
          button.setAttribute("data-bs-placement", "left");
          button.setAttribute("data-bs-title", "Copied!");
          tooltip = new bootstrap.Tooltip(button, 
            { trigger: "manual", 
              customClass: "code-copy-button-tooltip",
              offset: [0, -8]});
          tooltip.show();    
        }
        setTimeout(function() {
          if (tooltip) {
            tooltip.hide();
            button.removeAttribute("data-bs-title");
            button.removeAttribute("data-bs-toggle");
            button.removeAttribute("data-bs-placement");
          }
          button.setAttribute("title", currentTitle);
          button.classList.remove('code-copy-button-checked');
        }, 1000);
        // clear code selection
        e.clearSelection();
      });
      function tippyHover(el, contentFn, onTriggerFn, onUntriggerFn) {
        const config = {
          allowHTML: true,
          maxWidth: 500,
          delay: 100,
          arrow: false,
          appendTo: function(el) {
              return el.closest('section.slide') || el.parentElement;
          },
          interactive: true,
          interactiveBorder: 10,
          theme: 'light-border',
          placement: 'bottom-start',
        };
        if (contentFn) {
          config.content = contentFn;
        }
        if (onTriggerFn) {
          config.onTrigger = onTriggerFn;
        }
        if (onUntriggerFn) {
          config.onUntrigger = onUntriggerFn;
        }
          config['offset'] = [0,0];
          config['maxWidth'] = 700;
        window.tippy(el, config); 
      }
      const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
      for (var i=0; i<noterefs.length; i++) {
        const ref = noterefs[i];
        tippyHover(ref, function() {
          // use id or data attribute instead here
          let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
          try { href = new URL(href).hash; } catch {}
          const id = href.replace(/^#\/?/, "");
          const note = window.document.getElementById(id);
          return note.innerHTML;
        });
      }
      const findCites = (el) => {
        const parentEl = el.parentElement;
        if (parentEl) {
          const cites = parentEl.dataset.cites;
          if (cites) {
            return {
              el,
              cites: cites.split(' ')
            };
          } else {
            return findCites(el.parentElement)
          }
        } else {
          return undefined;
        }
      };
      var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
      for (var i=0; i<bibliorefs.length; i++) {
        const ref = bibliorefs[i];
        const citeInfo = findCites(ref);
        if (citeInfo) {
          tippyHover(citeInfo.el, function() {
            var popup = window.document.createElement('div');
            citeInfo.cites.forEach(function(cite) {
              var citeDiv = window.document.createElement('div');
              citeDiv.classList.add('hanging-indent');
              citeDiv.classList.add('csl-entry');
              var biblioDiv = window.document.getElementById('ref-' + cite);
              if (biblioDiv) {
                citeDiv.innerHTML = biblioDiv.innerHTML;
              }
              popup.appendChild(citeDiv);
            });
            return popup.innerHTML;
          });
        }
      }
    });
    </script>
    

</body></html>